RBC Capital analyst Shagun Singh raised the firm’s price target on Edwards Lifesciences (EW) to $100 from $95 and keeps an Outperform rating on the shares. The company has issued its 2026 outlook and reiterated its long-range plan at its Investor Day, and while the sentiment pre-event was positive given momentum in TAVR/TMTT, both are expected to continue into 2026, the analyst tells investors in a research note. RBC adds that it is positive on Edwards Lifesciences’ positioning in attractive end-markets, multiple catalysts, and valuation.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $92 from $90 at UBS
- Cautious Optimism for Edwards Lifesciences: Hold Rating Maintained Amid Back-End-Loaded Growth Expectations
- Edwards Lifesciences price target raised to $88 from $83 at Baird
- Edwards Lifesciences price target raised to $100 from $95 at Stifel
- Edwards Lifesciences price target raised to $89 from $84 at Canaccord